NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reiterated at D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a research note issued on Tuesday,Benzinga reports. They presently have a $31.00 price target on the stock.

NRXP has been the topic of several other research reports. Ascendiant Capital Markets upped their price objective on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. HC Wainwright reissued a “buy” rating and issued a $19.00 price target on shares of NRx Pharmaceuticals in a report on Monday, November 25th. Finally, EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st.

NRx Pharmaceuticals Trading Up 16.9 %

Shares of NRXP stock traded up $0.48 during mid-day trading on Tuesday, reaching $3.33. The stock had a trading volume of 333,779 shares, compared to its average volume of 2,428,315. The business has a 50-day simple moving average of $2.27 and a 200 day simple moving average of $1.91. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $7.33. The company has a market cap of $40.27 million, a P/E ratio of -1.56 and a beta of 1.08.

Insider Buying and Selling at NRx Pharmaceuticals

In other NRx Pharmaceuticals news, Chairman Jonathan C. Javitt bought 40,000 shares of NRx Pharmaceuticals stock in a transaction on Tuesday, December 17th. The stock was purchased at an average cost of $1.17 per share, for a total transaction of $46,800.00. Following the completion of the purchase, the chairman now directly owns 84,634 shares of the company’s stock, valued at $99,021.78. The trade was a 89.62 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 19.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On NRx Pharmaceuticals

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Anson Funds Management LP acquired a new stake in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 142,525 shares of the company’s stock, valued at approximately $241,000. Anson Funds Management LP owned approximately 1.33% of NRx Pharmaceuticals as of its most recent filing with the SEC. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.